Osteoarthritis in Medical Technology
Navigation Links
Osteoarthritis in Medical Technology
... was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA ... in the other group (P=0.006). The percentage of osteoarthritis Research Society International (OARSI) responders ... in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who ...
... its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, ... AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is ... with various safety issues, is not justified for osteoarthritis patients. The molecular properties of ESBA105 are ...
... effective treatment option for the symptoms of osteoarthritis of the knee, with an improved safety profile ... in the management of patients with symptomatic osteoarthritis involving joints accessible to these agents." ... in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. Patients in this five-arm, ...
... Results of FLEXX Trial Presented at the osteoarthritis Research Society International's 2008 World ... presented results from the FLEXX Trial of osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium ... saline (IA-saline) for the relief of pain in knee osteoarthritis (OA) at 26 weeks. The results of the trial of 586 ...
... 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of ... of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). ... is a side effect of particular concern in the osteoarthritis population. A post hoc pooled analysis of the ...
... -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 ... significant improvement in pain associated with osteoarthritis of the knee according to the primary efficacy ... and the prevalence increases with age.(2) osteoarthritis of the knee is a common type of this disorder, ...
... with moderate to severe chronic pain due to osteoarthritis showed that the efficacy and tolerability of ... patients with moderate to severe pain due to osteoarthritis of the hip or knee. Patients had required ... Western Ontario and McMaster Universities (WOMAC) osteoarthritis Index of pain, stiffness and function. Plasma ...
... (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is ... and safety trial in which 1020 patients with osteoarthritis of the knee have been enrolled at 150 clinical ... of drugs for treating the signs and symptoms of osteoarthritis and are the same as those used in the other two ...
... by Dr. Catherine Middleton-Hardie at the osteoarthritis Research Society International (OARSI) 2007 World Congress on osteoarthritis in Fort Lauderdale, Florida during the poster ... December 7 and Saturday, December 8, 2007, at the osteoarthritis Research Society International 2007 World ...
... acid (HA) for the relief of pain in patients with osteoarthritis (OA) of the knee at the American College of ... the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment ... weight hyaluronan for the treatment of osteoarthritis of the ....
... with orthopedic surgeries and management of osteoarthritis pain in the knee. These include a Phase 2 trial ... shoulder surgery, a Phase 2 / 3 trial in osteoarthritis of the knee, and a Phase 3 trial in Total Knee ... option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect ...
... with naproxcinod demonstrating clear efficacy in this difficult type of osteoarthritis patients and showing the same GI adverse event rate as placebo. The blood ... States, Canada and Europe. Eligible patients had a diagnosis of primary osteoarthritis of the hip of at least three months in duration and were randomized on a ...
... significant pain relief in patients with moderate to severe pain due to osteoarthritis of the hip or knee compared to placebo. Findings also showed that ALO-01 ... with placebo in 344 adult patients with moderate to severe pain due to osteoarthritis of the hip or knee. After a screening and washout period from previous ...
... were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days. Cardiovascular ...
... is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee. "The interest from surgeons and patients for a minimally ... Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market ...
... worsening hot flushes in the arzoxifene group. The data were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and osteoarthritis (ECCEO) annual meeting. Arzoxifene is being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction ...
... allowance from the Korea Food and Drug Administration (KFDA) to initiate a Phase IIa clinical trial of TissueGene-C (TG-C) in patients with severe osteoarthritis of the knee. TG-C has been developed for the localized delivery of allogeneic human cells expressing TGF-beta1 in order to induce the regeneration ...
... edition of the specialist journal "Osteoarthritis and Cartilage". The researchers followed 376 patients to determine the effectiveness of various osteoarthritis treatments. After six months as well as after two years, patients who received Orthokine therapy experienced significantly less pain and more ...
... opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, ...
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
... compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week ... as measured by the Western Ontario and McMaster osteoarthritis Index (WOMAC). In this study, patients on ... with placebo. "The disabling nature of osteoarthritis pain can greatly impact a person's life," said ...... its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). This double-blind, randomized, ... AG, commented, "As of today, no disease-modifying osteoarthritis drug exists, which is the key unmet need. OA is ... with various safety issues, is not justified for osteoarthritis patients. The molecular properties of ESBA105 are ...
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
... a recently completed positive study in chronic osteoarthritis pain of the knee. The decision does not ... clinical trials: one positive study in chronic osteoarthritis pain of the knee(i) and two studies(ii,iii), -- ... in the Treatment of Patients with osteoarthritis Knee Pain. Poster presented at the ...NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
... escalating doses of naproxcinod and naproxen in osteoarthritis (OA) patients with controlled hypertension. The ... represent a valuable treatment alternative for osteoarthritis patients," said Raymond Townsend, Professor of ... in a relevant population of chronically treated osteoarthritis patients with many cardiovascular risk factors ...... effective treatment option for the symptoms of osteoarthritis of the knee, with an improved safety profile ... in the management of patients with symptomatic osteoarthritis involving joints accessible to these agents." ... in the U.S. and Canada with symptoms of primary osteoarthritis of the knee. Patients in this five-arm, ...
... Results of FLEXX Trial Presented at the osteoarthritis Research Society International's 2008 World ... presented results from the FLEXX Trial of osteoarthritis of the Knee, showing that EUFLEXXA(R) (1% sodium ... saline (IA-saline) for the relief of pain in knee osteoarthritis (OA) at 26 weeks. The results of the trial of 586 ...
... 3 study for naproxcinod in 1020 patients with osteoarthritis of the knee (the 302 study). Both doses of ... of the knee and the ongoing 303 study in osteoarthritis of the hip, in addition to the 302 study). ... is a side effect of particular concern in the osteoarthritis population. A post hoc pooled analysis of the ...
Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
... new research findings on the genetics of osteoarthritis (OA) at the 2008 World Congress on Osteoarthritis, sponsored by the osteoarthritis Research Society International (OARSI). The 2008 World Congress on osteoarthritis takes place Sept. 18-21, 2008, at the Rome ...New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery
... the usefulness of arthroscopic surgery for osteoarthritis of the knee should encourage patients to consider ... the pain and stiffness of moderate to severe osteoarthritis of the knee as surgery. "This study offers hope ... supporting physical therapy for treatment of osteoarthritis of the knee, including: -- A report published ...Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
... French maritime pine tree, reduced overall knee osteoarthritis (OA) symptoms by 20.9 percent and lowered pain by ... Pycnogenol may help the joints to recover. With osteoarthritis cases on the rise, many are seeking ... traditional medication taken. The CDC estimates osteoarthritis affects 34 percent of all adults over the age of ...... -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 ... significant improvement in pain associated with osteoarthritis of the knee according to the primary efficacy ... and the prevalence increases with age.(2) osteoarthritis of the knee is a common type of this disorder, ...
NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
... Additional efficacy end points, like the Modified osteoarthritis Research Society International (OARSI) responder ... and naproxen- controlled trial, in patients with osteoarthritis of the knee. 918 eligible patients were ... old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, ...NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
... clinical trial for naproxcinod, in patients with osteoarthritis of the hip (the 303 study). 810 patients have ... in the 301 phase 3 study, in patients with osteoarthritis of the knee (see press release of October 27, ... The 302 study for naproxcinod in patients with osteoarthritis of the knee (see press release of April 3, 2007) ...... with moderate to severe chronic pain due to osteoarthritis showed that the efficacy and tolerability of ... patients with moderate to severe pain due to osteoarthritis of the hip or knee. Patients had required ... Western Ontario and McMaster Universities (WOMAC) osteoarthritis Index of pain, stiffness and function. Plasma ...
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
... -- The 301 study was conducted in patients with osteoarthritis of the knee and has provided successful ... -- The 302 study started enrolling patients with osteoarthritis of the knee in the U.S. in April 2007 and the ... 2007 in the U.S. and Europe, in patients with osteoarthritis of the hip. This study is expected to ...Osteoarthritis: Which Treatments Work and Which Don't?
... Findings appear in the February issue of osteoarthritis and Cartilage MT. LAUREL, N.J., Feb. 19 ... set of treatment recommendations for knee and hip osteoarthritis may help millions of people worldwide who live in ... recommendations appear in the February issue of osteoarthritis and Cartilage and can be found at ...... (303) is a 13-week trial in patients with osteoarthritis of the hip. Patient enrollment in this trial is ... and safety trial in which 1020 patients with osteoarthritis of the knee have been enrolled at 150 clinical ... of drugs for treating the signs and symptoms of osteoarthritis and are the same as those used in the other two ...
... by Dr. Catherine Middleton-Hardie at the osteoarthritis Research Society International (OARSI) 2007 World Congress on osteoarthritis in Fort Lauderdale, Florida during the poster ... December 7 and Saturday, December 8, 2007, at the osteoarthritis Research Society International 2007 World ...
... acid (HA) for the relief of pain in patients with osteoarthritis (OA) of the knee at the American College of ... the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment ... weight hyaluronan for the treatment of osteoarthritis of the ....
Anesiva Defines Regulatory Pathway for Adlea with FDA
... with orthopedic surgeries and management of osteoarthritis pain in the knee. Trials underway include a Phase ... shoulder surgery, a Phase 2 / 3 trial in osteoarthritis of the knee, and the two Phase 3 trials mentioned ... option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect ...Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
... is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary ... benefits to relieve knee pain caused by osteoarthritis and improve physical functioning, appear to be no ... from the pain and reduced mobility caused by osteoarthritis of the knee," said AHRQ Director Carolyn ...... with orthopedic surgeries and management of osteoarthritis pain in the knee. These include a Phase 2 trial ... shoulder surgery, a Phase 2 / 3 trial in osteoarthritis of the knee, and a Phase 3 trial in Total Knee ... option in the management of chronic osteoarthritis pain. Importantly, the prolonged analgesic effect ...
Applying Clinical Findings to the Practice of Medicine
... Osteoporosis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00232 ) and osteoarthritis ( http://orthoinfo.aaos.org/topic.cfm?topic=A00227 ) Skeletal ... tendon-to-bone insertion," stated Dr. Thomopoulos. Osteoporosis and osteoarthritis Hiroshi Kawaguchi, MD, Ph.D. and co-authors at the University of ...ESBATech's Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
... ESBA105 is also being studied in other therapeutic indications such as osteoarthritis (OA). Earlier this year, ESBATech initiated a Phase I/IIa clinical study to explore clinical activity of ESBA105 in osteoarthritis of the knee. About Cataract Surgery A cataract is a clouding of ...... with naproxcinod demonstrating clear efficacy in this difficult type of osteoarthritis patients and showing the same GI adverse event rate as placebo. The blood ... States, Canada and Europe. Eligible patients had a diagnosis of primary osteoarthritis of the hip of at least three months in duration and were randomized on a ...
... significant pain relief in patients with moderate to severe pain due to osteoarthritis of the hip or knee compared to placebo. Findings also showed that ALO-01 ... with placebo in 344 adult patients with moderate to severe pain due to osteoarthritis of the hip or knee. After a screening and washout period from previous ...
... were measured by Elecsys proBNP (Roche Diagnostics) in 433 patients with osteoarthritis of the knees, with or without osteoarthritis of the hands, during an observational period of 200 days. Cardiovascular ...
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
... from the first pivotal phase 3 trial for naproxcinod in patients with osteoarthritis of the knee (the 301 study) were presented on November 10, 2007 at the ... Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. ...... is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee. "The interest from surgeons and patients for a minimally ... Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market ...
Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
... of osteoporosis and the other product relates to the prevention of osteoarthritis -- osteoarthritis product has the potential to be the first disease- modifying drug that ...Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
... of osteoporosis and the other product relates to the prevention of osteoarthritis -- osteoarthritis product has the potential to be the first disease- modifying drug that ...Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
... opioid treatment for an extended period of time; and VOLTAREN(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) ...Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density
... data from the second Phase III trial called "NEXT" study were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and osteoarthritis (ECCEO) annual meeting. The third Phase III trial, the "GENERATIONS" Study, is a five-year, randomized, double-blind, placebo-controlled study ...... worsening hot flushes in the arzoxifene group. The data were presented at the European Society for Clinical and Economic Aspects of Osteoporosis and osteoarthritis (ECCEO) annual meeting. Arzoxifene is being studied for the prevention and treatment of osteoporosis in postmenopausal women and the reduction ...
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, ...... allowance from the Korea Food and Drug Administration (KFDA) to initiate a Phase IIa clinical trial of TissueGene-C (TG-C) in patients with severe osteoarthritis of the knee. TG-C has been developed for the localized delivery of allogeneic human cells expressing TGF-beta1 in order to induce the regeneration ...
Kensey Nash Announces IDE Submission for Cartilage Repair Device
... the knee and a majority of these are repeat procedures, illustrating the ineffectiveness of current therapeutic approaches. Over time, debilitating osteoarthritis may develop in the afflicted joint ultimately requiring partial or total knee replacement. The Company believes that an early and successful ...... edition of the specialist journal "Osteoarthritis and Cartilage". The researchers followed 376 patients to determine the effectiveness of various osteoarthritis treatments. After six months as well as after two years, patients who received Orthokine therapy experienced significantly less pain and more ...
... opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, ...
Other ContentssporessporessporessporesspondylosissprainsportssportssportssportssportssprainssprainssprainssquamoussquamoussquamoussquamoussquamoussputumsputumspurspurspurspurOther TagsAHAAHALongevitmeremereOther Tagstendency 2tendency 3tendency 4tendency 5tendency 6tendency 7tendency 8tendency 9tendency 10alcoholic 2alcoholic 3alcoholic 4alcoholic 5alcoholic 6powerful 2powerful 3powerful 4powerful 5powerful 6powerful 7powerful 8powerful 9powerful 10voluntary 2voluntary 3voluntary 4voluntary 5voluntary 6voluntary 7voluntary 8voluntary 9voluntary 10spreading 2spreading 3spreading 4habitats 2habitats 3habitats 4habitats 5organs 2organs 3organs 4organs 5organs 6organs 7organs 8organs 9organs 10transplanted 2transplanted 3transplanted 4transplanted 5transplanted 6
(Date:11/30/2009)...CLEMSON Clemson University researchers Ron Falta ...nmental Protection Agency grant to study the safe ... located deep below the earth,s surface. , With ... believed to be the leading cause of global warmin...promising alternatives for reducing emissions usin...
(Date:11/30/2009)...w Orleans, LA Researchers from LSU Health Science...ce Kennedy Shriver National Institute of Child Hea...of Public Health, Brigham and Women,s Hospital, an... time that drinking more than 5 servings of sugar-...to significantly elevate the risk of developing di...
(Date:11/30/2009)...o so-called invasion proteins are crucial for infe...ce of human cells, which stimulates the host cell ...molecules exert a different function, for example ...he group,s results have now been published in the ...y ". , Spoiled meat is one of the sources for L...
Breaking Biology News(10 mins):Sugary cola drinks linked for first time to higher risk of gestational diabetes 2Sugary cola drinks linked for first time to higher risk of gestational diabetes 3It takes 2 to infect 2Healthnostics Medbioworld com Portal Web Site to Include Social Networking Features 14385 1Healthnostics Medbioworld com Portal Web Site to Include Social Networking Features 14385 2United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdin 14383 1United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdin 14383 2United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdin 14383 3United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdin 14383 4DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications 28OHSA 29 Suite for SIRO Clinpharm 5294 1DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications 28OHSA 29 Suite for SIRO Clinpharm 5294 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications 28OHSA 29 Suite for SIRO Clinpharm 5294 3(Date:11/30/2009)..., , NEW YORK, Nov. 30 /PRNewswire/...ted States who are living with HIV/AIDS, nearly ha...fection rates in Washington, D.C. have surpassed t...r and Black women account for more than 90 percent...n,s capitol. On Tuesday, December 1 at 6:00 p.m.*,...
(Date:11/30/2009)..., After nearly two years of development and exten...nstitute for Quality and Efficiency in Health Care...elation between cost and benefit. The Institute ca...commissions awarded by the Federal Joint Committee... for passing on recommendations to the GKV-Spitzen...
(Date:11/30/2009)... Language, social skills improve with specially de...Nov. 30 (HealthDay News) -- A special, intensive e... succeeded in boosting IQ along with children,s la..."When done in this fashion, many children are able...ldine Dawson, lead author of the study, published ...
(Date:11/30/2009)..., , WASHINGTON, Nov. 30 - S...or A Cause" on Monday, December 7(th) to raise fun... childhood terminal diseases. All proceeds from ea...e Children,s Research Hospital. ,, Salon Leau ...years. The salon is owned by LoAnn Lai, widely rec...
(Date:11/30/2009)..., , BRIDGEWATER, N.J., Nov. 30 /PRNewswir...g U.S. provider of meeting logistics, speaker prog... for the life sciences industry, announced it has ...he state by NJBIZ, New Jersey,s leading statewide ... top fifty businesses that have made significant c...
Breaking Medicine News(10 mins):Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 2Health News:BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 2Health News:IQWiG presents a method for evaluating the relation between cost and benefit 3Health News:IQWiG presents a method for evaluating the relation between cost and benefit 4Health News:IQWiG presents a method for evaluating the relation between cost and benefit 5Health News:Working Intensely Early on May Help Autistic Kids 2Health News:Working Intensely Early on May Help Autistic Kids 3Health News:Working Intensely Early on May Help Autistic Kids 4Health News:Georgetown Hair Salon Helps St. Jude Find A Cure 2Health News:Advanced Health Media Honored at NJ Finest Award Ceremony 2[1] BET Networks Joins the International Call to Stop the Spread of HIV on World Aids Day Tuesday, December 1 with an Annual Special Episode of '106 & PARK' and on the Ground Initiatives Through BET's Award Winning Public Affairs Campaign Rap-It-Up[0] IQWiG presents a method for evaluating the relation between cost and benefit[0] Working Intensely Early on May Help Autistic Kids[0] Georgetown Hair Salon Helps St. Jude Find A Cure[0] Advanced Health Media Honored at NJ Finest Award Ceremony
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |